PI3K/AKT/mTOR通路
蛋白激酶B
癌症研究
癌变
信号转导
卵巢癌
细胞生长
生物
医学
RPTOR公司
癌症
mTORC2型
mTORC1型
内科学
细胞生物学
生物化学
作者
Meran Keshawa Ediriweera,Kamani Hemamala Tennekoon,Sameera R. Samarakoon
标识
DOI:10.1016/j.semcancer.2019.05.012
摘要
Ovarian cancer (OC) is a lethal gynecological cancer. The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway plays an important role in the regulation of cell survival, growth, and proliferation. Irregularities in the major components of the PI3K/AKT/mTOR signaling pathway are common in human cancers. Despite the availability of strong pre-clinical and clinical data of PI3K/AKT/mTOR pathway inhibitors in OC, there is no FDA approved inhibitor available for the treatment of OC. Here, we outline the importance of PI3K/AKT/mTOR signaling pathway in OC tumorigenesis, proliferation and progression, and pre-clinical and clinical experience with several PI3K/AKT/mTOR pathway inhibitors in OC.
科研通智能强力驱动
Strongly Powered by AbleSci AI